Xencor, Inc. revenue breakdown overview

Xencor, Inc. revenue for the last year amounted to 168.34 M USD, the most of which — 168.34 M USD — came from its highest performing source at the moment, Monoclonal Bispecific Antibody and Cytokine Therapeutics, the year earlier bringing 164.58 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Xencor, Inc. 168.34 M USD, and the year before that — 164.58 M USD.